Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 13/20 | 0.78 |
| ▸ | INSR | P06213 | 9/20 | 0.78 |
| ▸ | IGF1R | P08069 | 9/20 | 0.78 |
| ▸ | EGFR | P00533 | 10/20 | 0.73 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.72 |
| ▸ | AURKA | O14965 | 1/20 | 0.72 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.72 |
| ▸ | JAK2 | O60674 | 1/20 | 0.72 |
| ▸ | STK10 | O94804 | 1/20 | 0.72 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.72 |
| ▸ | SLC34A2 | O95436 | 1/20 | 0.72 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.72 |
| ▸ | ABL1 | P00519 | 1/20 | 0.72 |
| ▸ | CD74 | P04233 | 1/20 | 0.72 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.72 |
| ▸ | LCK | P06239 | 1/20 | 0.72 |
| ▸ | FYN | P06241 | 1/20 | 0.72 |
| ▸ | FES | P07332 | 1/20 | 0.72 |
| ▸ | CSF1R | P07333 | 1/20 | 0.72 |
| ▸ | YES1 | P07947 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31196996 | 1.00 | ALK (0.78) | ALKINSRIGF1REGFRCHEK1 | |
| SCHEMBL16780721 | 0.97 | ALK (0.74) | ALKINSRIGF1REGFRCHEK1 | |
| SCHEMBL15600820 | 0.97 | ALK (0.74) | ALKINSRIGF1REGFRCHEK1 | |
| SCHEMBL16780999 | 0.96 | ALK (0.72) | ALKINSRIGF1REGFRCHEK1 | |
| SCHEMBL15600815 | 0.95 | ALK (0.72) | ALKINSRIGF1REGFRCHEK1 | |
| SCHEMBL15600811 | 0.94 | ALK (0.71) | ALKINSRIGF1REGFRCHEK1 | |
| SCHEMBL15600769 | 0.94 | ALK (0.71) | ALKINSRIGF1REGFRCHEK1 | |
| SCHEMBL14150200 | 0.94 | ALK (0.74) | ALKINSRIGF1REGFREML4 | |
| SCHEMBL15600816 | 0.93 | ALK (0.73) | ALKINSRIGF1REGFRCHEK1 | |
| SCHEMBL22497639 | 0.93 | ALK (0.71) | ALKINSRIGF1REGFRCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220227796-A1 | EGFR INHIBITORS, COMPOSITIONS AND METHODS THERE OF | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2022-07-21 | — | — | US | claimed |
| CN-113677680-A | EGFR inhibitor and composition and application thereof | 贝达药业股份有限公司 | 2021-11-19 | — | — | CN | claimed |
| EP-2844642-B1 | COMPOUNDS FOR INHIBITING CELL PROLIFERATION IN EGFR-DRIVEN CANCERS | ARIAD PHARMA INC (US) | 2019-11-13 | — | — | EP | claimed |
| US-9834571-B2 | Compounds for inhibiting cell proliferation in EGFR-driven cancers | ARIAD PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | claimed |
| CN-119143806-B | Dimethyl phosphine oxide substituted aniline pyrimidine derivative targeting EGFR mutation, preparation method and application thereof, and medicine prepared from dimethyl phosphine oxide substituted aniline pyrimidine derivative | 四川大学华西医院 | 2025-03-11 | — | — | CN | disclosed |
| CN-119143806-A | Dimethyl phosphine oxide substituted aniline pyrimidine derivative targeting EGFR mutation, preparation method and application thereof, and medicine prepared from dimethyl phosphine oxide substituted aniline pyrimidine derivative | 四川大学华西医院 | 2024-12-17 | — | — | CN | disclosed |
| CN-113677680-B | EGFR inhibitor, composition and application thereof | 贝达药业股份有限公司 | 2024-05-10 | — | — | CN | disclosed |
| US-20220227796-A1 | EGFR INHIBITORS, COMPOSITIONS AND METHODS THERE OF | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2022-07-21 | — | — | US | disclosed |
| CN-113677680-A | EGFR inhibitor and composition and application thereof | 贝达药业股份有限公司 | 2021-11-19 | — | — | CN | disclosed |
| WO-2020200191-A1 | EGFR INHIBITORS, COMPOSITIONS AND METHODS THERE OF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2020-10-08 | — | — | WO | disclosed |
| EP-2844642-B1 | COMPOUNDS FOR INHIBITING CELL PROLIFERATION IN EGFR-DRIVEN CANCERS | ARIAD PHARMA INC (US) | 2019-11-13 | — | — | EP | disclosed |
| US-10350210-B2 | EGFR and ALK dual inhibitor | PRECEDO PHARMACEUTICALS CO., LTD (CN) | 2019-07-16 | — | — | US | disclosed |
| US-9834571-B2 | Compounds for inhibiting cell proliferation in EGFR-driven cancers | ARIAD PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834571-B2 | Compounds for inhibiting cell proliferation in EGFR-driven cancers | ARIAD PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| WO-2017101803-A1 | NOVEL EGFR AND ALK DUAL INHIBITOR | 合肥中科普瑞昇生物医药科技有限公司 | 2017-06-22 | — | — | WO | disclosed |
| US-20160244469-A1 | Compounds for Inhibiting Cell Proliferation in EGFR-Driven Cancers | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-25 | — | — | US | disclosed |
| US-20160244469-A1 | Compounds for Inhibiting Cell Proliferation in EGFR-Driven Cancers | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-25 | — | — | US | disclosed |
| US-20150166591-A1 | METHODS AND COMPOSITIONS FOR RAF KINASE MEDIATED DISEASES | ARIAD PHARMACEUTICALS, INC. | 2015-06-18 | — | — | US | disclosed |
| US-20150166591-A1 | METHODS AND COMPOSITIONS FOR RAF KINASE MEDIATED DISEASES | ARIAD PHARMACEUTICALS, INC. | 2015-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166591-A1 | METHODS AND COMPOSITIONS FOR RAF KINASE MEDIATED DISEASES | BRAF, RAF1, EGFR | ALK 161/4885INSR 856/4885IGF1R 675/4885 |
| US-10350210-B2 | EGFR and ALK dual inhibitor | ALK, EGFR, ERBB2 | ALK 1/4885INSR 969/4885IGF1R 212/4885 |
| US-20220227796-A1 | EGFR INHIBITORS, COMPOSITIONS AND METHODS THERE OF | EGFR, ERBB2, ERBB3 | ALK 56/4885INSR 324/4885IGF1R 49/4885 |
| US-20160244469-A1 | Compounds for Inhibiting Cell Proliferation in EGFR-Driven Cancers | EGFR, MKI67, ERBB2 | ALK 293/4885INSR 726/4885IGF1R 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.